Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etelcalcetide vs cinacalcet in hemodialysis patients with secondary hyperparathyroidism
CTR20170593Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of etelcalcetide in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Started Apr 2018; status: completed.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on CTR20170593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170593.